4P-PHARMA
14.3.2024 11:36:29 CET | Business Wire | Press release
4P-Pharma, a clinical-stage biotech based in Lille dedicated to developing curative therapies for serious untreated diseases, is thrilled to announce the appointment of Jérôme Vailland as Chief Financial Officer (CFO) for 4P-Pharma and its subsidiaries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314228336/en/
Jérôme Vailland 4P-Pharma Chief Financial Officer (Photo: Business Wire)
Jérôme Vailland built a solid career with significant contributions at Ernst & Young (EY), where he worked for 10+ years. He gained extensive experience in financial audit, company structuring, transactions, and IPOs across European and American markets, mainly in life sciences. Over the years, he held several positions up to Senior Manager, managing and advising numerous clients while assuming broader technical and managerial responsibilities.
Following his strong experience at EY, Jérôme joined Horama, now Coave Therapeutics, in 2016, serving as Chief Financial Officer. He successfully raised funds for the company by leveraging his strategic and leadership skills. In 2020, he became Chief Financial Officer of a biotechnology company listed on the Euronext Paris regulated market, focusing on developing tools and services for genome modification analysis and control.
These positions underscore his deep understanding of the financial challenges faced by public and private biotech companies and the practical solutions that must be implemented to deliver efficient results.
By joining the company's executive team, Jérôme Vailland will contribute to supporting the company's growth, especially through effective and transparent financial management. Jérôme Vailland's recognized finance skills and excellent understanding of organization structuring will be an asset for 4P-Pharma.
Revital Rattenbach, CEO of 4P-Pharma, stated: "As 4P-Pharma celebrates a decade of innovation, we welcome Jérôme Vailland as our new CFO. His experience and skills in finance are essential for our growth and transition into a successful organization. With Jérôme’s leadership, we look forward to a future of stability and continued success, reassuring our investors and partners in the pharmaceutical community of our commitment to excellence and sustainability."
Regarding his appointment as Chief Financial Officer, Jérôme Vailland said, "I am thrilled to join 4P-Pharma at a decisive moment, especially with two drug candidates prepared to enter Phase II clinical trials. I look forward to working with the team and exploring all scientific and financial options to advance the mission of 4P-Pharma and its subsidiaries."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class therapies to patients rapidly. 4P-Pharma leverages drug candidates with reduced development timelines, thanks partly to regulatory opportunities ("emergency use" or conditional marketing authorization) with strong intellectual property. The company is based in Lille and Paris and has over 20 employees.
Website: https://4p-pharma.com/en
LinkedIn: https://www.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma
The only legally binding version of the 4P-Pharma press release is the one in its original language. Translations should be compared to the source text, which takes precedence. The press release text resulting from a translation should not be considered official.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314228336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release
Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g
Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press release
Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilitiesReference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availabilitySecond strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platformInitial 1.25 GW is backed by a hyperscaler customer contract for deployment in TexasEnergy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026 Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release
IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom